The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase II study of cabozantinib for patients with advanced RET-rearranged lung cancers.
 
Alexander E. Drilon
Honoraria - Exelixis; Genentech/Roche; Ignyta
Consulting or Advisory Role - Exelixis; Genentech/Roche
Speakers' Bureau - Ignyta
Research Funding - Foundation Medicine
Travel, Accommodations, Expenses - Exelixis; Genentech/Roche; Ignyta
 
Camelia S. Sima
No Relationships to Disclose
 
Romel Somwar
No Relationships to Disclose
 
Roger Smith
No Relationships to Disclose
 
Michelle S. Ginsberg
No Relationships to Disclose
 
Gregory J. Riely
Honoraria - Celgene
Consulting or Advisory Role - ARIAD; Mersana; Novartis; Roche
Research Funding - GlaxoSmithKline (Inst); Infinity Pharmaceuticals (Inst); Millennium (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - Novartis
 
Charles M. Rudin
Consulting or Advisory Role - Abbvie; AVEO; Boehringer Ingelheim; GlaxoSmithKline; Merck
Research Funding - Biomarin
 
Marc Ladanyi
No Relationships to Disclose
 
Mark G. Kris
Consulting or Advisory Role - ARIAD; AstraZeneca; Clovis Oncology; Daiichi Sankyo; Exelixis; Genentech/Roche; Novartis; Pfizer; Threshold Pharmaceuticals
Research Funding - Pfizer (Inst); Puma Biotechnology (Inst)
 
Naiyer A. Rizvi
No Relationships to Disclose